Analyst Price Targets — ARCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 12:52 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $7.42 | StreetInsider | '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler |
| January 22, 2026 9:08 pm | — | Roth Capital | $20.00 | $7.59 | TheFly | Arcturus Therapeutics initiated with a Buy at Roth Capital |
| August 22, 2025 11:45 am | Lili Nsongo | Leerink Partners | $54.00 | $18.51 | TheFly | Arcturus Therapeutics price target lowered to $54 from $63 at Leerink |
| May 28, 2025 11:11 am | Greg Harrison | Scotiabank | $32.00 | $11.82 | TheFly | Arcturus Therapeutics initiated with an Outperform at Scotiabank |
| March 10, 2025 9:14 am | Thomas Shrader | BTIG | $48.00 | $14.55 | StreetInsider | BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| November 11, 2024 12:11 pm | Whitney Ijem | Canaccord Genuity | $10.58 | $3.02 | StreetInsider | Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity |
| August 6, 2024 8:27 am | Whitney Ijem | Canaccord Genuity | $10.30 | $3.20 | TheFly | Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord |
| July 2, 2024 6:38 am | Ed Arce | H.C. Wainwright | $8.58 | $3.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| May 31, 2024 7:40 am | Yasmeen Rahimi | Piper Sandler | $20.02 | $5.64 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT) |
| May 10, 2024 7:24 am | Whitney Ijem | Canaccord Genuity | $12.30 | $3.83 | TheFly | Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord |
Latest News for ARCT
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026…
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARCT.
U.S. House Trading
No House trades found for ARCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.